Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
11β-HSD1/11β-HSD2 Inhibitor
DG 381B is a selective inhibitor of 11β-HSD1 and 11β-HSD2, enzymes involved in the regulation of glucocorticoid metabolism. By inhibiting these enzymes, DG 381B plays a significant role in modulating cortisol levels, which can impact metabolic processes and inflammatory responses. This compound is valuable for research applications related to metabolic diseases, hypertension, and other conditions associated with glucocorticoid action. -
11β-HSD1 Inhibitor
MK-0736 hydrochloride is a potent and selective inhibitor of 11β-HSD1, a key enzyme involved in glucocorticoid metabolism. This compound has shown significant antihypertensive effects and is valuable for research into metabolic syndrome and related disorders. Clinical studies indicate that MK-0736 hydrochloride possesses a favorable safety profile, making it a promising candidate for further exploration in hypertension-related research. -
11β-HSD1 Inhibitor
INU-101 is a selective, orally active inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). It demonstrates potent inhibitory activity in liver microsomes from mouse, monkey, and human sources, effectively enhancing insulin sensitivity and reducing fasting blood glucose levels. This compound is applicable in research focused on metabolic diseases, particularly diabetes, making it a valuable tool for studying metabolic pathways and potential therapeutic strategies. -
11β-HSD1 Inhibitor
(R)-BMS-816336 is a selective inhibitor of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme. It demonstrates potent inhibitory activity with IC50 values of 14.5 nM for human, 50.3 nM for mouse, and 16 nM for cynomolgus monkey 11β-HSD1. This compound is applicable in research focused on metabolic disorders, obesity, and diabetes due to its role in modulating glucocorticoid metabolism. -
11β-HSD Inhibitor
Clofutriben (ASP3662) is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). By inhibiting this enzyme, Clofutriben plays a critical role in modulating cortisol metabolism, thereby influencing glucocorticoid signaling pathways. This compound is primarily utilized in research related to metabolic disorders, obesity, and stress response. Its applications include evaluating the therapeutic potential of targeting 11β-HSD1 in various disease models. -
11β-HSD Inhibitor
11β-HSD1-IN-16 is a selective inhibitor of the 11β-hydroxysteroid dehydrogenase HSD11B1, with an IC50 of 0.34 μM. This compound has key applications in research related to neuropathic pain, inflammatory pain, and occipital neuralgia. Its ability to modulate glucocorticoid metabolism makes it an important tool for understanding the role of 11β-HSD in various pain pathways. -
11β-HSD1 Inhibitor
11β-HSD1-IN-15 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1), effectively blocking the conversion of corticosterone to cortisol. By binding to the enzyme's active site, it serves as a valuable tool for investigating the role of 11β-HSD1 in various pathological conditions. This compound is particularly relevant for research on metabolic syndrome, obesity, cognitive decline, and type 2 diabetes, enabling insights into therapeutic strategies targeting these disorders. -
11β-HSD Inhibitor
11β-HSD1-IN-14 is a selective inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) with an IC50 of 74 nM for human HSD1 and 603 nM for HSD1 expressed in HEK293 cells. This compound demonstrates significant potential for modulating cortisol metabolism, making it relevant for research in metabolic disorders, obesity, and stress-related conditions. Its specificity supports studies aimed at elucidating the role of 11β-HSD1 in various physiological and pathological processes. -
11β-HSD1 Inhibitor
JTT-654 is a potent and selective inhibitor of 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1), exhibiting an IC50 of 4.65 nM for the human enzyme. This compound acts competitively against human recombinant 11β-HSD1 while demonstrating minimal inhibition of 11β-HSD2 (IC50 > 30 μM). JTT-654 has been shown to improve insulin resistance and alleviate non-obese type 2 diabetes by targeting 11β-HSD1 in adipose tissue and the liver, making it a valuable tool for studying metabolic disorders. -
11β-HSD1 Inhibitor
BVT-2733 hydrochloride is a selective, nonsteroidal inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). With an IC50 of 96 nM for the mouse enzyme, it exhibits lower potency against the human variant (IC50 of 3341 nM). This compound is valuable for investigating the role of 11β-HSD1 in the pathophysiology of arthritis and obesity-related conditions, providing insights into therapeutic strategies for these diseases. -
11β-HSD Inhibitor
BVT-3498 is a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a key enzyme in glucocorticoid metabolism. By selectively blocking 11β-HSD1 activity, BVT-3498 modulates local cortisol levels, which is critical for research into metabolic diseases and stress-related disorders. This compound serves as a valuable tool in elucidating the role of 11β-HSD1 in various physiological and pathological processes. -
15-PGDH Inhibitor
MF-DH-300 is a selective inhibitor of 15-PGDH, a key enzyme in the degradation of prostaglandins. By inhibiting this enzyme, MF-DH-300 enhances prostaglandin levels, which may have therapeutic implications in muscle disorders, such as spinal muscular atrophy (SMA). This compound is valuable for research focused on understanding the role of prostaglandins in muscle-related pathologies and developing potential interventions. -
15-PGDH Inhibitor
ML148 is a potent and selective inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), exhibiting an IC50 of 56 nM. This compound is particularly valuable for the investigation of prostaglandin signaling pathways, which play critical roles in inflammation, pain, and various physiological processes. ML148’s specificity and inhibitory capacity make it a crucial tool for exploring the modulation of prostaglandin metabolism in various biological contexts. -
15-PGDH Inhibitor
HW201877 is an effective and orally active inhibitor of 15-prostaglandin dehydrogenase (15-PGDH) with an IC50 value of 3.6 nM. This compound significantly increases PGE2 levels in A549 cells and has demonstrated notable efficacy in preclinical models of tissue injury and fibrosis. HW201877 is suitable for investigating inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and Crohn’s disease (CD). -
15-PGDH Inhibitor
15-PGDH-IN-4 is a potent inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), exhibiting an IC50 value of 1.2 nM against human 15-PGDH. This reagent is valuable for research into immune cell function and tissue regeneration, enabling the exploration of metabolic pathways and inflammatory processes. Its ability to modulate 15-PGDH activity makes it a critical tool for studies aimed at understanding and manipulating prostaglandin signaling. -
15-PGDH Inhibitor
(R)-SW033291 is a potent and high-affinity inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). By inhibiting this enzyme, (R)-SW033291 significantly increases levels of prostaglandin E2 (PGE2) in bone marrow and other tissues. This compound has potential applications in research focused on tissue regeneration and the modulation of inflammatory responses associated with prostaglandin signaling. -
15-PGDH Inhibitor
MF-PGDH-008 is a selective inhibitor of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This compound plays a crucial role in modulating prostaglandin levels, offering significant potential in research focused on inflammation and cancer biology. Its ability to inhibit 15-PGDH makes it valuable for exploring therapeutic strategies aimed at enhancing prostaglandin signaling in various biomedical studies. -
15-PGDH Inhibitor
15-PGDH-IN-3 is a selective competitive inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This compound plays a critical role in regulating prostaglandin levels and can be utilized to study the modulation of inflammatory responses and cancer progression. Its inhibition of 15-PGDH may have implications in various research applications, including pain management and the investigation of therapeutic targets in oncology. -
15-PGDH Inhibitor
CAY10397 is a selective and orally bioavailable inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It effectively inhibits the production of endogenous metabolites dependent on 15-PGDH, and it has been shown to block selenium-dependent protective mechanisms in inflammation. CAY10397 is primarily utilized in research related to colitis and other inflammatory conditions, providing insights into the role of 15-PGDH in disease pathology. -
15-PGDH Inhibitor
15-epi-PGE1 is a stereoisomer of Prostaglandin E1 that functions as a non-competitive inhibitor of human placental 15-Hydroxyprostaglandin dehydrogenase (15-PGDH). With an IC50 value of 170 μM, this compound exhibits inhibitory activity that can be utilized in studies of prostaglandin metabolism. Research applications may include investigations into the roles of prostaglandins in various physiological and pathological processes. -
15-PGDH Inhibitor
15-PGDH-IN-2 is a potent inhibitor of 15-PGDH, displaying an IC50 value of 0.274 nM. This compound is valuable for researching biological processes such as hair loss, bone formation, gastric ulcer healing, and dermal wound healing. Its ability to modulate 15-PGDH activity makes it a useful tool in studying pathways associated with these conditions. -
HSD17B13 Inhibitor
BI-3231 is a potent and selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating IC50 values of 1 nM and 13 nM for human and mouse HSD17B13, respectively. This compound is valuable for research into nonalcoholic steatohepatitis (NASH) and various liver disorders, facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers a promising avenue for understanding and potentially treating these conditions. -
AKR1C3 Inhibitor
AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibiting an IC50 value of 0.56 μM. This compound is particularly relevant for investigations into castrate-resistant prostate cancer (CRPC), where AKR1C3 plays a crucial role in tumor progression and hormone regulation. Its mechanism facilitates the exploration of therapeutic strategies targeting metabolic pathways in cancer research. -
17β-HSD1 Inhibitor
17β-HSD1-IN-1 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2. This compound plays a crucial role in modulating estrogen levels and is pertinent for research focused on non-small cell lung cancer (NSCLC). Its specificity enables targeted studies into the enzymatic pathways associated with hormone-driven tumorigenesis. -
AKR1C3 Inhibitor
S07-1066 is a selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) that enhances the cytotoxic effects of doxorubicin (DOX). By inhibiting the AKR1C3-mediated reduction of DOX, S07-1066 effectively reverses drug resistance in cells that overexpress this enzyme. This compound is valuable for research applications investigating chemotherapy resistance and potential adjuvant therapies in cancer treatment. -
17β-HSD10 Inhibitor
17β-HSD10-IN-1 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), exhibiting oral bioavailability and effective blood-brain barrier penetration. This compound is characterized by a selective mechanism of action that minimizes off-target effects on mitochondria, along with a favorable safety profile devoid of cytotoxic or neurotoxic effects. It is suitable for research applications focused on disorders related to steroid metabolism and neurodegenerative diseases. -
HSD17B1 Inhibitor
Linustedastatum is an orally active inhibitor of hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1). This compound exhibits significant biological activity by modulating the biosynthesis of estrogens, making it a valuable tool for research applications related to endometriosis. Its mechanism of action provides insights into hormonal pathways and potential therapeutic targets in gynecological disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-2 is a selective inhibitor of HSD17B13, demonstrating human IC50 values of 0.18 μM with β-estradiol and 0.25 μM with Leukotriene B4. This compound binds to the active site of HSD17B13 in an NAD+-dependent manner, interacting with the bound NAD+ cofactor to stabilize the HSD17B13 protein and prevent its aggregation. HSD17B13-IN-2 effectively reduces the conversion of β-estradiol to estrone in cellular assays, making it a valuable tool for investigating nonalcoholic fatty liver disease and related metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-3 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of 0.38 μM and 0.45 μM in biochemical assays using β-estradiol and Leukotriene B4 (LTB4) as substrates, respectively, in the presence of NAD+ as a cofactor. This compound is useful for studying the role of HSD17B13 in steroid metabolism and has potential applications in research related to metabolic disorders and inflammatory conditions. However, it exhibits low cell penetration, which may limit its use in certain cellular assays. -
HSD17B13 Inhibitor
HSD17B13-IN-10 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of 0.01 μM. This compound is valuable in researching liver diseases by modulating steroid metabolism and influencing lipid and glucose homeostasis. Its selective inhibition makes it a critical tool for studying the pathogenic mechanisms underlying hepatic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-41 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates potential in modulating pathways associated with liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its application in research can aid in understanding the underlying mechanisms of these diseases and support the development of novel therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-29 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is a valuable tool for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as metabolic and cardiovascular disorders. Its selectivity for HSD17B13 positions it as a significant reagent for investigating therapeutic strategies targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-49 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into various liver-related conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). Its inhibition of HSD17B13 may provide insights into potential therapeutic strategies for metabolic and cardiovascular disorders linked to liver dysfunction. -
HSD17B13 Inhibitor
HSD17B13-IN-69 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an impressive IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition profile makes HSD17B13-IN-69 a crucial tool for exploring therapeutic strategies and understanding disease mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-67 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in studying liver diseases and metabolic disorders, providing valuable insights into the role of HSD17B13 in these conditions. Its high specificity and efficiency make it a useful tool for researchers investigating the therapeutic potential of targeting HSD17B13. -
17β-HSD10 Inhibitor
17β-HSD10-IN-2 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), a multifunctional enzyme located in the mitochondria. This compound demonstrates significant inhibition of 17β-HSD10 without causing off-target effects on mitochondrial function or exhibiting cytotoxic and neurotoxic properties. 17β-HSD10-IN-2 is valuable for research applications focused on Alzheimer's disease and hormone-dependent cancers, facilitating the exploration of therapeutic strategies targeting this enzyme. -
HSD17B13 Inhibitor
HSD17B13-IN-73 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool for investigating the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic strategies targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-70 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to liver diseases and metabolic disorders, providing critical insights into the enzymatic regulation of steroid metabolism. HSD17B13-IN-70 serves as a valuable tool for investigators studying the role of HSD17B13 in various biological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-97 is a highly potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 µM. This compound holds promise for investigating therapeutic strategies for nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 makes it a valuable tool for exploring lipid metabolism and liver pathology in preclinical research. -
17β-HSD5 Inhibitor
17β-HSD5 Inhibitor 3 is a selective inhibitor of the enzyme 17β-HSD5, exhibiting an IC50 value of 69 nM. This compound plays a crucial role in modulating steroid metabolism and can be utilized in research related to steroid-related disorders and hormonal regulation. Its oral bioactivity makes it a valuable tool for exploring therapeutic approaches in conditions influenced by 17β-HSD5 activity. -
HSD17B13 Inhibitor
HSD17B13-IN-15 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is of significant interest in the study of various liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. HSD17B13-IN-15 provides valuable insights for research related to drug-induced liver injury (DILI) and potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-93 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 for estradiol within the range of 0.1 to 0.5 μM. This compound is valuable for investigating the role of HSD17B13 in liver pathologies, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-93 serves as a critical tool for advancing research in these areas. -
HSD17B13 Inhibitor
HSD17B13-IN-6 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. This compound is valuable for investigating the role of HSD17B13 in liver diseases, providing insights that may contribute to the understanding of metabolic disorders and potential therapeutic targets. Researchers can utilize HSD17B13-IN-6 to explore biochemical pathways associated with liver function and disease processes. -
HSD17B13 Inhibitor
HSD17B13-IN-80-d2 is a deuterium-labeled inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is essential for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its unique labeling enhances tracking and analysis in metabolic research applications. -
17β-HSD10 Inhibitor
17β-HSD10-IN-3 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with an IC50 value of 5.59 μM. This compound demonstrates a lack of cytotoxicity in the HEK-293 cell line at concentrations up to 20 μM. It is suited for research applications investigating the role of 17β-HSD10 in steroid metabolism and neurodegenerative diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-76 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research into liver diseases and metabolic disorders, facilitating studies on the biochemical pathways regulated by HSD17B13 and its role in steroid metabolism. -
17β-HSD3 Inhibitor
BMS-856 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3). It demonstrates potent inhibitory activity with IC50 values of 60 nM in enzyme assays and 300 nM in whole cell assays, effectively disrupting the enzyme's activity. BMS-856 is valuable for research focused on steroidogenesis and potential therapeutic applications in hormonal disorders, particularly those related to testosterone metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-74 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool in the study of liver diseases and metabolic disorders, enabling the exploration of HSD17B13's role in steroid metabolism. Its potent inhibition can facilitate research into therapeutic strategies targeting related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-86 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its ability to modulate HSD17B13 activity makes it a useful tool in the exploration of therapeutic strategies for these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-52 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver conditions, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies related to drug-induced liver injury (DILI).
